On today's episode of TDR's Trade To Black podcast, we're joined by Payton Nyquvest, Founder and CEO of Numinus Wellness (OTCMKTS: NUMIF), to discuss the latest advancements in psychedelic-assisted therapy. Nyquvest talks about Numinus' recent $6 million funding success, strategic partnerships, and the future of MDMA-assisted therapy for mental health.


Key highlights include:

🎙️The significance of the FDA's acceptance of MDMA for therapy and its implications for Numinus and the field at large.
💡The strategic collaboration with Optimi Health Corp, aiming to enhance the development and delivery of psychedelic therapies.
🤝The financial strategies Numinus is employing to reduce its burn rate to zero, ensuring sustainability and growth.
🌐The importance of experiential training for therapists in psychedelic-assisted therapies and how Numinus is leading the charge.
💼The potential impact of Health Canada's stance on psychedelic therapies following FDA approvals.
🎤Nyquvest's vision for the future of psychedelic-assisted therapy and Numinus' role in making these transformative treatments accessible to those in need.

This episode provides a comprehensive look into the efforts and challenges of integrating psychedelic-assisted therapies into mainstream healthcare, showcasing Numinus Wellness Inc.'s pivotal role in this emerging field.